Lars Lannfelt
Tracked across 4 events · 36 articles · First seen May 08, 2026 · Last active Sep 22, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Lars Lannfelt was re-elected as an ordinary board member of BioArctic.
May 28, 2026 · 9 articles
Tech
BioArctic announced that Leqembi (lecanemab), the first therapy targeting an underlying cause of Alzheimer's disease, is now available at a private clinic in Sweden and that the first patient has started treatment. This marks the…
Impact: Lars Lannfelt is the researcher whose work at Uppsala University led to the discovery of the Arctic mutation and the development of Leqembi.
Sep 22, 2026 · 7 articles
Business
Impact: Professor Lars Lannfelt's discovery of the Arctic mutation in Alzheimer's disease formed the basis for the development of Lecanemab by BioArctic.
May 15, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Lars Lannfelt live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard